An active immunosuppressive pathway is identified in colon cancer that confers immune evasion by the cancer and can be targeted to synergize with immunotherapies.
This is a preview of subscription content, log in via an institution to check access.
Marina Corral Spence/Springer Nature
References
Dyck, L. & Mills, K.H.G. Eur. J. Immunol. 47, 765–779 (2017).
Toh, J.W.T. et al. Clin. Colorectal Cancer 15, 285–291 (2016).
Pitt, J.M. et al. Immunity 44, 1255–1269 (2016).
Xiao, Q. et al. Nat. Med. 24, 262–270 (2018).
Nusse, R. & Clevers, H. Cell 169, 985–999 (2017).
Malladi, S. et al. Cell 165, 45–60 (2016).
D'Amico, L. et al. J. Exp. Med. 213, 827–840 (2016).
Patsoukis, N., Li, L., Sari, D., Petkova, V. & Boussiotis, V.A. Mol. Cell. Biol. 33, 3091–3098 (2013).
Marçais, A. et al. Nat. Immunol. 15, 749–757 (2014).
Cichocki, F. et al. Cancer Res. 77, 5664–5675 (2017).
McCubrey, J.A. et al. Oncotarget 5, 2881–2911 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Marçais, A., Walzer, T. An immunosuppressive pathway for tumor progression. Nat Med 24, 260–261 (2018). https://doi.org/10.1038/nm.4508
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4508
- Springer Nature America, Inc.
This article is cited by
-
Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer
Journal of Nanobiotechnology (2021)
-
Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells
Cell Death Discovery (2019)